INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Successful left atrial appendage occlusion with    │ successful left atrial appendage occlusion with    │      85 │
│ Amplatzer or WATCHMAN device within 37 days before │ Amulet device within 37 days prior to              │         │
│ randomization                                      │ randomization                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Life expectancy of fewer than 18 months            │ life expectancy of less than 18months              │      87 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Left atrial thrombus on an imaging study performed │ left atrial thrombus on transesophageal            │      88 │
│ after successful left atrial appendage closure but │ echocardiography study performed after successful  │         │
│ before enrollment                                  │ left atrial appendage closure but before           │         │
│                                                    │ enrollment                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Indications to dual antiplatelet therapy other     │ indications to dual antiplatelet therapy other     │      93 │
│ than atrial fibrillation and/or left atrial        │ than atrial fibrillation or left atrial appendage  │         │
│ appendage occlusion at the time of enrollment or   │ occlusion at the time of enrollment or predicted   │         │
│ predicted appearance of such indications within    │ appearance of such indications within the duration │         │
│ the duration of the trial (e.g. planned coronary   │ of the trial (eg. coronary artery disease)         │         │
│ revascularization)                                 │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known allergy to clopidogrel and/or                │ known allergy to clopidogrel or acetylsalicylic    │      97 │
│ acetylsalicylic acid precluding its administration │ acid precluding its administration as specified by │         │
│ as specified by the protocol                       │ the protocol                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic kidney disease stage IV and V              │ chronic kidney disease stage IV and V              │      97 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participant is willing to sign the study informed  │ participant is willing to sign the study informed  │      98 │
│ consent form                                       │ consent form                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Indications to anticoagulation at the time of      │ indications to anticoagulation at the time of      │      98 │
│ enrollment and/or predicted appearance of such     │ enrollment or predicted appearance of such         │         │
│ indications within the duration of the trial (e.g. │ indications within the duration of the trial (eg.  │         │
│ pulmonary embolism)                                │ pulmonary embolism)                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any known inborn or acquired coagulation disorders │ any known inborn or acquired coagulation disorders │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treatment with dual antiplatelet therapy           │ treatment with dual antiplatelet therapy           │      99 │
│ (clopidogrel and acetylsalicylic acid) between     │ (clopidogrel and acetylsalicylic acid) between     │         │
│ left atrial appendage closure and randomization    │ left atrial appendage closure and randomization    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participant's age 18 years or older at the time of │ participant's age 18 years or older at the time of │      99 │
│ signing the informed consent form                  │ signing the informed consent form                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in other clinical studies with       │ participation in other clinical studies with       │      99 │
│ experimental therapies at the time of enrollment   │ experimental therapies at the time of enrollment   │         │
│ and preceding 3 months                             │ and preceding 3 months                             │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years                  │ chronic kidney disease stage IV and V              │      34 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participant is willing to follow all study         │ participant is willing to follow all study         │      72 │
│ procedures; especially the randomized antiplatelet │ procedures; especially randomized antiplatelet     │         │
│ treatment regimen                                  │ treatment regimen and follow-up visits with        │         │
│                                                    │ transesophageal echocardiography when applicable   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women who are pregnant or breastfeeding; women of  │ women who are pregnant or breast feeding; women of │      75 │
│ childbearing potential who do not consent to apply │ childbearing potential who do not consent to apply │         │
│ at least two methods of contraception. This        │ at least to methods of contraception. This         │         │
│ criterion does not apply to women 2 years post     │ criterion does not apply to postmenopausal women   │         │
│ menopause (with negative pregnancy test 24 hours   │                                                    │         │
│ prior to randomization if \<55 years old) or after │                                                    │         │
│ surgical sterilization                             │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Peridevice leak \>5mm on imaging study preceding   │ peridevice leak >5mm on transesophageal            │      76 │
│ enrollment                                         │ echocardiography study preceding enrollment        │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Participation in other clinical studies with       │ poor tolerance of or technical difficulties with   │      46 │
│ experimental therapies at the time of enrollment   │ performing transesophageal echocardiography        │         │
│ and preceding 3 months                             │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participant is willing to follow all study         │ participant is willing to follow all study         │      72 │
│ procedures; especially the randomized antiplatelet │ procedures; especially randomized antiplatelet     │         │
│ treatment regimen                                  │ treatment regimen and follow-up visits with        │         │
│                                                    │ transesophageal echocardiography when applicable   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women who are pregnant or breastfeeding; women of  │ women who are pregnant or breast feeding; women of │      75 │
│ childbearing potential who do not consent to apply │ childbearing potential who do not consent to apply │         │
│ at least two methods of contraception. This        │ at least to methods of contraception. This         │         │
│ criterion does not apply to women 2 years post     │ criterion does not apply to postmenopausal women   │         │
│ menopause (with negative pregnancy test 24 hours   │                                                    │         │
│ prior to randomization if \<55 years old) or after │                                                    │         │
│ surgical sterilization                             │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Peridevice leak \>5mm on imaging study preceding   │ peridevice leak >5mm on transesophageal            │      76 │
│ enrollment                                         │ echocardiography study preceding enrollment        │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 86
Average Levenshtein Ratio of individual lines: 83.2
OverAll Ratio: 84.6
